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Inflammation is a major contributor to tubular epithelium injury in kidney disorders, and the involvement of blood platelets in
driving inflammation is increasingly stressed. CD154, the ligand of CD40, is one of the mediators supporting platelet
proinflammatory properties. Although hypoxia is an essential constituent of the inflammatory reaction, if and how platelets and
CD154 regulate inflammation in hypoxic conditions remain unclear. Here, we studied the control by CD154 of the
proinflammatory cytokine interleukin- (IL-) 6 secretion in short-term oxygen (O2) deprivation conditions, using the HK-2 cell
line as a kidney tubular epithelial cell (TEC) model. IL-6 secretion was markedly stimulated by CD154 after 1 to 3 hours of
hypoxic stress. Both intracellular IL-6 expression and secretion were stimulated by CD154 and associated with a strong
upregulation of IL-6 mRNA and increased transcription. Searching for inhibitors of CD154-mediated IL-6 production by HK-2
cells in hypoxic conditions, we observed that chloroquine, a drug that has been repurposed as an anti-inflammatory agent,
alleviated this induction. Therefore, CD154 is a potent early stimulus for IL-6 secretion by TECs in O2 deprivation conditions, a
mechanism likely to take part in the deleterious inflammatory consequences of platelet activation in kidney tubular injury. The
inhibition of CD154-induced IL-6 production by chloroquine suggests the potential usefulness of this drug as a therapeutic
adjunct in conditions associated with acute kidney injury.
1. Introduction
Accumulating evidence underscores the association and
interdependence of hypoxic and inflammatory pathways.
Indeed, hypoxia is a common feature of inflamed tissues,
being linked for a large part to an unbalanced oxygen (O2)
demand/supply [1]. Over the past years, the role of hyp-
oxia in controlling inflammation has been increasingly
appreciated [2]. Hypoxia is linked to the progression of
inflammation via intricate mechanisms. On the one hand,
hypoxia can stimulate the expression of proinflammatory
cytokines via various pathways, including those involving
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the Hypoxia-Inducible Factor-1 (HIF-1) pathway; on the
other hand, hypoxia also drives anti-inflammatory responses
[2]. Hypoxia is also associated with an endoplasmic reticulum
(ER) stress [3, 4], and the production of inflammatory cyto-
kine secretion is an outcome of the ER stress [3, 4]. Neverthe-
less, much remains to be understood on how hypoxia
pathways cooperatively operate on the different stages of
inflammation. Hypoxia pathways not only drive pro- and
anti-inflammatory responses but are also regulated, for exam-
ple, by inflammatory mediators themselves, indicating com-
plex feedback loops in the natural history of inflammation.
Acute kidney injury (AKI) is an important example of how
inflammatory and hypoxic pathways interdepend. In sepsis
and ischemia/reperfusion-associated AKI, current pathophys-
iological concepts give a significant role to tubulointerstitial
inflammatory events [5]. Inflammation orchestrates the dele-
terious sequence of events that result in microcirculatory
alterations and tubular cell injury in AKI and hypoxia is both
a driver of injury and long-term outcome in AKI [6–8].
Among the plethora of inflammatory mediators involved,
clinical and experimental studies have underscored the con-
tribution of interleukin- (IL-) 6 to renal injury in kidney
inflammatory conditions, including AKI [9]. IL-6 mediates
acute inflammation in response to tissue damage, being
involved in both inflammation promotion and resolution
and tissue restorative response [10, 11], and has been impli-
cated in inflammatory disorders [12]. Via the production of
inflammatory mediators such as IL-6, tubular epithelial cells
(TECs) contribute to AKI-associated inflammation [13].
Indeed, TECs are not only targets of inflammatory mediators
but also active participants in kidney inflammation in
response to inflammatory challenges, providing ground for
self-amplifying inflammatory loops [14, 15]. The mecha-
nisms of IL-6 production in a hypoxic/inflammatory context
remain however ill understood. Additionally, constitutive
and induced IL-6 expressions in TECs are not inhibited by
glucocorticoids, emphasizing the need to understand how
this cytokine is regulated for the management of kidney
tubular inflammation [16].
Several studies support a role for platelets in driving
tubular inflammation in AKI [17]. Hemodynamic distur-
bances and various inflammatory and coagulation pathways
activate platelets resulting in the generation of a range of pro-
inflammatory mediators. Among them, CD154, the ligand of
CD40, is an upstream regulator of inflammation; the induc-
tion of proinflammatory cytokines is a major outcome of
CD154 binding to CD40, as shown in various cells and TECs
in particular [13, 18, 19]. CD154 is deleterious in AKI associ-
ated with ischemia/reperfusion, as the inhibition of CD40
signaling is protective, but underlying mechanisms remain
unclear [20]. CD154 may be important in initiating and sus-
taining inflammation in kidney tubules via the induction of
proinflammatory cytokines. However, little is known on
how CD154 exerts its proinflammatory role in the context
of hypoxia. Coincidental occurrence of inflammation and
hypoxia and cross-regulations between hypoxic and inflam-
matory pathways underline the importance to understand
how proinflammatory cytokine expression is regulated
under hypoxic conditions. Here, we used HK-2 cells as
a TEC model to study the control of IL-6 secretion by
CD154 in O2 deprivation conditions. Looking for inhibi-
tors of IL-6 induction by CD154, we examined the poten-
tial role of chloroquine, a drug long used in the treatment
or prevention of malaria, which has found its application
expanded to treat inflammatory diseases [21, 22].
2. Materials and Methods
2.1. Cell Culture. The immortalized human proximal TEC
cell line HK-2 was from the American Tissue Type Culture
Collection (LGC standards, Molsheim, France). Cultures
were free of mycoplasma as evaluated by polymerase chain
reaction (PCR) [23]. Cells were routinely grown in complete
medium consisting of Dulbecco’s modified Eagle’s medium
(DMEM, Gibco, ThermoFisher Scientific, Illkirch, France,
glucose concentration 1 g/L), containing 10% fetal calf serum
(FCS), 100 IU/mL penicillin, and 100μg/mL streptomycin.
Cultures were routinely carried out under normoxic condi-
tions. Experiments in hypoxic conditions (0.1% O2) were
performed in a hypoxia incubator chamber (BioSpherix®,
NY, USA). Culture media were deoxygenated for 24-48 hours
at 0.1% O2 before use. Cells were grown in multiple well
plates for various times. In some experiments, cultures were
also performed in gas-permeable cell culture plates (Sarstedt,
Marnay, France). For CD154 treatment, recombinant soluble
CD154 (rsCD154, MegaCD40LTM, Coger SAS, Paris,
France) was added at the beginning of hypoxic cultures and
used routinely at a concentration of 100ng/mL, a dose com-
parable to what was used in previous studies [24, 25]. In
dose-effect experiments, rsCD154 was used at concentrations
ranging from 1 to 200ng/mL. Cytokines interleukin-1α (IL-
1α), tumor necrosis factor-α (TNF-α), and interferon-γ
(IFN-γ) were from ImmunoTools (Friesoythe, FRG). Cyto-
kine concentrations (IL-1α (200 IU/mL), TNF-α (10 ng/mL,
200 IU/mL), or interferon-γ (200 IU/mL)) were chosen
according to previous studies on CD40 expression [26, 27].
Hydrocortisone and acetylsalicylic acid (gift from Bordeaux
Hospital) were used at 1μg/mL for hydrocortisone [28] and
50μg/mL for acetylsalicylic acid [29, 30], respectively. In acti-
nomycin D experiments, actinomycin D (Sigma-Aldrich,
Saint-Quentin-Fallavier, France) was used at a concentration
of 5μg/mL and added to cells 30mins before starting the
culture in hypoxia. In cycloheximide experiments, cyclohex-
imide (Sigma-Aldrich) was used at a concentration of
50μg/mL and added to cells 15mins before starting the cul-
ture in hypoxia. In chloroquine experiments, cells were pre-
incubated for 30mins with chloroquine diphosphate salt
(Sigma-Aldrich) at concentrations ranging from 12.5 to
100μg/mL before starting the culture in hypoxia.
2.2. Enzyme-Linked Immunosorbent Assay (ELISA). Interleu-
kin-6 (IL-6) concentrations in culture supernatants or in cell
lysates were measured with commercial ELISA kits (R&D
Systems, France, and RayBiotech, Tebu-Bio, France, respec-
tively), according to the manufacturer’s recommendations.
For cell lysate measurements, cells were lysed in RIPA buffer
(Sigma-Aldrich) supplemented with a protease inhibitor
cocktail (Sigma-Aldrich). Cell lysates were prepared as
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described in Western Blotting. VEGF, IL-1β, and TNF-α in
cell culture supernatants were measured with ELISA kits
from R&D Systems.
2.3. PCR and Real-Time Quantitative PCR (RT-qPCR). Total
RNA was extracted from HK-2 cells using a RNA extraction
kit (Macherey-Nagel, Hoerdt, France) following the manu-
facturer’s instructions. RNA integrity was assayed using the
Agilent RNA Screen Tape Assay Bioanalyzer 2200 (Agilent
Technologies, Les Ulis, France). Complementary DNA
(cDNA) was synthesized using hexaprimers and oligo-dT
from 1μg of total RNA in a final volume of 20μL, using the
First-Strand cDNA Synthesis Kit for RT-PCR (Quantitect
Reverse Transcription Kit (Sigma-Aldrich)), according to
the manufacturer’s instructions. The qPCR was performed
in duplicate on a CFX 384 (Bio-Rad, Marnes-la-Coquette,
France) using SYBR® Premix Ex Taq™ bulk (Takara,
Ozyme). Cycling parameters for the qPCR reaction included
a 3mins hot start followed by 40 cycles of denaturation at
90°C for 10 seconds, annealing at 60°C for 30 seconds, and
elongation at 72°C for 30 seconds. Post-PCR melt curve was
performed (65°C to 95°C/0.5° each 5 seconds). Ribosomal
protein lateral stalk subunit P0 (RPLP0) and 18S rRNA were
used as internal controls. Relative expression levels were cal-
culated using the 2−ΔΔCt method after normalization to the
expression of the endogenous 18S rRNA reference gene and
were presented as the fold increase relative to the control
[31]. IL-6 primers were from Sino Biological (Interchim,
Montluçon, France). CD40 and XBP1 primers used andmea-
surement of the ratio spliced to unspliced XBP1 mRNA
(XBP1s/u) were performed as described [32].
2.4. Nascent RNA Experiments. Nascent RNAs were purified
from total RNA using a Click-iT Nascent RNA Capture Kit
(ThermoFisher Scientific) according to the manufacturer’s
instructions. Briefly, biotin-azide was attached to nascent
5-ethynyl uridine- (EU-) labelled RNA using click-it chemis-
try. The EU-labelled nascent RNAs were then purified using
MyOne Streptavidin T1 magnetic Dynabeads (ThermoFisher
Scientific). cDNA synthesis was then performed on magnetic
bead-captured RNAs, using the VILO cDNA synthesis kit
(ThermoFisher Scientific) and real-time qPCR performed.
RNA final concentration and purity (OD 260/280) were
determined using a NanoPhotometer® P 330 (Implen
GmbH, Munich, Germany). Real-time qPCR experiments
were performed in duplicate using a Takyon ROX SYBR 2X
MasterMix dTTP blue (Kaneka Eurogentec S.A., Belgium)
using cDNA diluted 1 : 50 and the following program: 95°C
for 5min as initial denaturation and 40 cycles of 95°C for
15 sec and 61°C for 30 sec for amplification in a CFX
Connect™ Real-Time PCR Detection System (Bio-Rad Labo-
ratories, Hercules, CA, USA). Target gene expression was
quantified using the cycle threshold (Ct) values, and relative
expression levels were calculated according to the 2−ΔΔCt
method using RPLP0 as reference gene. Primers used for
IL-6 were from Sino Biological, and primer sequences used
for RPLP0 were 5′ CCTCGTGGAAGTGACATCGT 3′ and
5′ ATCTGCTTGGAGCCCACATT 3′.
2.5. Western Blotting. Cells were lysed in RIPA buffer (Sigma-
Aldrich) supplemented with a protease inhibitor cocktail
(Sigma-Aldrich). Cell lysate were obtained after centrifuga-
tion at 15000g for 10mins, at 4°C. Protein quantification
was performed using the Pierce BCA Protein Assay kit
(ThermoFisher Scientific). Samples were denatured in SDS-
PAGE buffer containing 2% SDS and 5% β-mercaptoethanol.
Samples, 10μg protein, were then separated on a 10 or 15%
acrylamide-bis acrylamide gel. After transfer (Immobilon-P
membrane, Merck Millipore, Molsheim, France), mem-
branes were blocked with TBST (TBS containing 0.1% Tween
20) containing 2.5% bovine serum albumin (BSA) and then
incubated overnight with the indicated antibody at 1μg/mL
at 4°C. After several washes with TBST, the membrane was
incubated for 1 hour at RT with the appropriate secondary
antibody conjugated to HRP. The detection was performed
using an enhanced chemiluminescent substrate, ECL plus
(GE Healthcare, Aulnay-sous-Bois, France), and images were
analyzed with an Image Quant LAS 4000 mini camera.
2.6. Immunofluorescence Microscopy. Cells grown on cover-
slips were fixed in 4% paraformaldehyde (PFA) for 10mins.
For permeabilization, after several washes with TBS, cells
were incubated for 10mins in 0.1% Triton X100, washed in
TBS, and incubated in blocking buffer (TBS containing 1%
BSA and 1% FCS). Cells were then incubated with a mouse
monoclonal anti-CD40 antibody, at a 1/100 dilution (Santa-
Cruz Biotechnology, Heidelberg, FRG) in blocking buffer,
for 2 hours, at RT. After several washes, cells were incubated
with Alexa Fluor® 488 goat anti-mouse antibody (Molecular
Probes, Invitrogen, France) at a 1/200 dilution, for 1 hour at
RT. After several washes, nuclei were labelled with 1μg/mL
of DAPI solution for 1min. Then, coverslips were mounted
on slides using Fluoromount-G (SouthernBiotech, USA).
For negative control, cells were incubated with matched iso-
type immunoglobulin and secondary antibody. Samples were
analyzed with a confocal microscope (Leica Microsystems,
France) and Leica software.
2.7. Flow Cytometry. Cytometry was performed on an Epics
XL2 (Beckman Coulter) flow cytometer working under the
EXPO 32 ADC software (Beckman Coulter). HK-2 cells
were incubated for 2 hours at RT with anti-CD40 monoclo-
nal antibodies (Santa-Cruz Biotechnologies, clone H-10,
Clinisciences, France) at 10μg/mL in phosphate-buffered
saline (PBS) containing 1% BSA. Cells were washed once
with PBS and further incubated for 30mins at RT with a
1/400 dilution of Alexa Fluor 488 (Molecular Probes) sec-
ondary antibody.
2.8. Viability, Apoptosis, Toxicity, and Proliferation Assays.
Lactate dehydrogenase Pierce colorimetric kit assay (Life
Technologies SAS, Courtaboeuf, France) was used to mea-
sure cellular cytotoxicity. Cell counts were performed on a
Malassez cell. Anti-human Fas agonistic mAb 7C11 anti-
body, a gift of F Belloc, Université de Bordeaux, was used in
apoptosis experiments. Apoptosis measurement was per-
formed by flow cytometry with the annexin V-FITC apopto-
sis staining/detection kit (Abcam, France).
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2.9. Antibodies Used in This Study Are Described in
Supplemental Material and Method Section
2.9.1. Statistical Analysis.Data were generated from indepen-
dent experiments and are presented as mean ± SD. Compar-
ison between groups was determined using the one-sample
t-test, Mann-Whitney test, or Kruskal-Wallis test as appro-
priate. All tests were two-sided, and a p value < 0.05 was
taken to indicate statistical significance. Statistical analyses
were performed using GraphPad Prism version 6.00 (Graph-
Pad Software, La Jolla, CA, USA).
3. Results
3.1. HK-2 Cells Are a Relevant Cellular Model to Assess
CD154-CD40 Function. In order to investigate the control
of IL-6 secretion by CD154 on HK-2 cells, we first assessed
the expression and functionality of the CD40, the main
receptor of CD154, which localizes at the cell surface after
its transport along the secretory pathway. As expected [33],
HK-2 cells expressed CD40 at the cell surface as monitored
by flow cytometry (Figure 1(a)) and its total expression (sur-
face and intracellular pool) was confirmed by immunofluo-
rescence microscopy (Figure 1(b)). As previously reported
[18], CD40 mRNA expression was stimulated by inflam-
matory mediators such as TNF-α, IFN-γ, and IL-1α
(Figure 1(c)). IL-1α was a strong inducer of CD40 at both
mRNA and protein levels [14] (Figures 1(c) and 1(d)).
CD154 binding to CD40 on HK-2 cells was functional as
shown by the corresponding activation of known down-
stream effectors, extracellular signal-regulated (ERK) and
c-Jun N-terminal (JNK) kinases (Figure 1(e)) [34]. We
next studied whether CD40 expression was modified by
hypoxic conditions. CD40 mRNA and protein expression
were not modified by hypoxic culture conditions or follow-
ing a reoxygenation step up to 24 hours hypoxic challenge
(Figures 2(a)–2(c)). A moderate but significant reduction
of CD40 expression was observed following a 48-hour hyp-
oxic period (Figure 2(c)), which could be related to various
mechanisms, including reduced transcription and protein
synthesis, that we have not explored further.
3.2. Resistance of HK-2 Cells to Hypoxic Conditions and
Association to Stress Responses. We next studied the func-
tional responses of HK-2 cells to hypoxic challenge by incu-
bating cells in O2 deprivation conditions. Previous studies
already demonstrated that 1% O2 conditions for up to 48
hours of culture did not induce apoptosis or necrosis in
HK-2 cells [35, 36]. We analyzed HK-2 cell susceptibility to
more severe hypoxic stress, 0.1% O2 conditions during 24
hours. As reported for 1% O2 culture conditions, no signifi-
cant increase of apoptosis or loss of viability following
hypoxic challenge (Figures 3(a) and 3(b)) or following
hypoxia/reoxygenation (not shown) was detectable. O2 dep-
rivation mitigated cell growth, and rsCD154 did not stimu-
late HK-2 proliferation in normal growth condition or
hypoxic condition (Figure 3(c)).
We next examined the activation of several stress path-
ways induced under hypoxic condition. First, we assessed in
the experimental conditions used the expression of two tran-
scription factors, HIF-1α and HIF-2α, which are upregulated
in hypoxic conditions and whose activity controls the expres-
sion of several genes essential for cell adaption under hypoxic
stress. As expected, O2 deprivation increased HIF-1α and
HIF-2α protein expression in HK-2 cells (Figure 4(a)); treat-
ment of HK-2 cells with rsCD154 did not modify HIF-1α
expression (Figure 4(a)). We also studied the expression of
one HIF-1α target genes, vascular endothelial growth factor
(VEGF), and observed that 0.1% O2 hypoxic condition led
to the accumulation of VEGF in culture supernatants
(Figure 4(b)). In these conditions, treatment of cells with
rsCD154 did not affect VEGF expression (Figure 4(b)).
Second, we assessed whether hypoxic conditions induced
ER stress and its adaptive response, the Unfolded Protein
Response (UPR), which are commonly associated with hyp-
oxia [37]. To study ER stress, we monitored UPR markers,
such as BiP/GRP78, phosphorylated eukaryotic translation-
initiation factor 2α (eIF2α), and the expression of the alterna-
tive spliced form of XBP-1 mRNA. ER stress induction
depended on the duration of hypoxia. Indeed, ER stress
markers were not detectable for short hypoxic challenges
such as 1 or 3 hours and could only be detected at 24 hours
and later times (Figure 4(c)). Increased splicing of XBP-1
mRNA was also only observed at late times depicting bell-
shaped curve kinetics (Figure 4(d)) and CD154 increased
XBP1 mRNA splicing (Figure 4(d)) as previously reported
[32]. In a condition mimicking anoxia in which cells were
incubated for 1 hour with 50ng/mL antimycin A, a mito-
chondrial respiratory chain blocking agent, XBP-1 mRNA
splicing was only minimally induced and no effect of
CD154 was detectable. However, upon the removal of anti-
mycin A, mimicking reoxygenation, XBP-1 mRNA splicing
was further increased and the enhancing effect of CD154
was apparent (Supplemental Figure 1).
Altogether, these results showed that HIF-1α and HIF-2α
inductions are early features of hypoxic stress in HK-2 cells
and that ER stress could only be observed at late culture
times, being likely related to the addition of other ER
stress-promoting signals during the progression of cell cul-
ture, such as glucose depletion [38]. No effects of rsCD154
on HIF-1α or on ER stress markers were observed at early
hypoxia times.
3.3. CD154 Stimulates IL-6 Secretion by HK-2 Cells in
Hypoxic Conditions.We then investigated the regulatory role
of CD154 on IL-6 secretion in short-term hypoxic stress con-
ditions, with the aim to study the contribution of CD154 in
the regulation of the expression of inflammatory mediators
in hypoxic conditions. We worked with short stimulation
times to remain close to pathophysiological conditions
encountered during acute inflammation. IL-6 was investi-
gated as it is a primary mediator of acute inflammation,
together with IL-1β and TNF-α, cytokines also involved at
the early stages of inflammation [39]. To determine the
rsCD154 concentration, dose-response effect experiments
were performed. We observed that rsCD154 dose-
dependently stimulated the expression of IL-6 after a 3-
hour hypoxic stress with a net increase at 100ng/mL and
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Figure 1: CD40 expression by HK-2 cells. (a, b) CD40 expression by HK-2 cells was analyzed by flow cytometry to assess the surface
expression of CD40 (a) and immunofluorescence microscopy to assess the total expression (surface and intracellular pool) (b; nuclei are
counterstained with DAPI). (c, d) HK-2 cells were treated with IL-1α (200 IU/mL), TNF-α (200 IU/mL), or interferon-γ (200 IU/mL) for
24 hours and CD40 mRNA expression analyzed by RT-qPCR (c) (n = 4, ∗significant relatively to control), or by flow cytometry (d) (n = 3,
∗significant relatively to control). (e) Treatment of HK-2 cells with rsCD154 activates ERK and JNK pathways. HK-2 cells were incubated
with rsCD154 and cells lysed at indicated time points. Cell lysates were subjected to SDS-PAGE and immunoblotted with indicated
antibodies.
5Mediators of Inflammation
no significant difference between doses of 100 and 200ng/mL
(Figure 5(a)).
We next studied the regulatory role of rsCD154 on IL-6
secretion in various hypoxic stress short-term periods. IL-6
secretion was not induced by a short hypoxic stress of 10
and 30min upon treatment with 100ng/mL rsCD154
(Figure 5(b)). The secretion of IL-6 was upregulated in the
presence of rsCD154 after a 1- or 3-hour hypoxic stress
(Figure 5(b)) and after hypoxia-reoxygenation (Figure 5(c)).
We also tested whether, in hypoxic conditions, rsCD154 reg-
ulated the expression of IL-1β and TNF-α cytokines. Neither
IL-1β nor TNF-α was induced upon brief hypoxic challenge
for 3 hours, even in the presence of rsCD154 at 100ng/mL
(data not shown). IL-6 measurements in cell lysates
confirmed secretion studies, showing that, under hypoxic
conditions, treatment with rsCD154 stimulated intracellular
IL-6 content following a 1- or 3-hour hypoxic stress
(Figure 5(d)). A reduced intracellular IL-6 expression level
was observed after 3 hours alongside to the increased IL-6
secretion. Additional mechanisms may be triggered to pre-
vent excessive upregulation of IL-6 expression upon O2 dep-
rivation. The induction of IL-6 secretion by rsCD154 in
hypoxia was not due to differences in cell death or prolifera-
tion (Figures 3(a)–(c)). A similar induction of IL-6 secretion
was observed also in gas-permeable plates (Supplemental
Figure 2). Altogether, the rapid CD154-mediated induction
of IL-6 in hypoxic conditions suggested a role for CD154 in
an early control of IL-6 production by HK-2 cells in
conditions associated with hypoxia.
3.4. CD154 Is a Strong Inducer of IL-6 mRNA Expression in
HK-2 Cells in Hypoxic Conditions. The addition of rsCD154
stimulated the expression of IL-6 mRNA in HK-2 cells in
hypoxic conditions (Figure 6(a)). Therefore, the stimulation
of IL-6 production by CD154 in hypoxic conditions was
associated with an increased expression of IL-6 mRNA, and
underlying mechanisms were next studied. rsCD154 treat-
ment did not result in an increased IL-6 mRNA abundance
when actinomycin D was added to inhibit transcription
(Figure 6(b)). The addition of cycloheximide resulted in a
decrease of IL-6 protein expression within one hour in HK-
2 cells, indicating instability of the IL-6 protein; however,
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Figure 2: CD40 expression is not modified by hypoxic stress. (a, b) HK-2 cells were incubated under normoxic or hypoxic conditions during
24 hours and CD40 expression analyzed by RT-qPCR (a) (n = 3) or flow cytometry (b) (n = 3). (c) HK-2 cells were subjected to different
hypoxic times followed by a 24-hour culture in normoxic conditions and CD40 expression analyzed by flow cytometry (n = 3, ∗significant
relatively to normoxic control).
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no stabilization of IL-6 protein by CD154 could be observed
(Figure 6(c)). Altogether, these results indicated a rapid and
strong induction of IL-6 mRNA expression by HK-2 cells
in hypoxia. The absence of detectable mRNA increase by
CD154 in experiments in which transcription was blocked
by actinomycin D suggested regulation acting at the tran-
scriptional level. To monitor the change in de novo IL-6
mRNA synthesis induced by CD154 in hypoxic conditions,
we use a nascent RNA capture assay on HK-2 cells grown 3
hours under hypoxic conditions. Results (Figure 6(d))
showed that CD154 stimulates the transcription of IL-6 gene
under hypoxic conditions.
3.5. Chloroquine Alleviates the CD154-Mediated Induction of
IL-6 in HK-2 Cells. Discovering inhibitors of the induction of
IL-6 in inflammatory conditions is an important medical
issue; this is particularly true for AKI in sepsis systemic
inflammatory response that remains a devastating complica-
tion due to the lack of efficient treatment. An efficient control
of inflammation has not yet been attained in this context.
Chloroquine is acknowledged to have anti-inflammatory
properties, as for example, its administration result in lower-
ing proinflammatory cytokines in patients with inflamma-
tory conditions [22]. We therefore examined the potential
role of chloroquine in the CD154-mediated induction of
IL-6 secretion in HK-2 cells following a 3-hour hypoxic stress
(Figure 7(a)). The induction of IL-6 secretion by CD154 was
dose-dependently reduced in chloroquine-treated HK-2 cells
(Figure 7(b)). Taken together, these results suggested that
chloroquine is able to reduce the induction by CD154 of
IL-6 secretion in HK-2 cells. We also tested steroidal and
nonsteroidal anti-inflammatory drugs, such as hydrocorti-
sone (HC) and acetylsalicylic acid (ASA) but did not observe
a reduction of CD154-mediated induction of IL-6 secretion
upon treatment with hydrocortisone or acetylsalicylic acid
at the dose and conditions that were used (Figure 7(c)).
4. Discussion
Proinflammatory cytokines are key players in the progression
of inflammation, and much remains to be understood on
mechanisms that regulate the cytokine network in hypoxia.
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7Mediators of Inflammation
Results of our study indicate that CD154 is an early and
strong inducer of IL-6 secretion in HK-2 cells grown under
O2 deprivation conditions. The induction of IL-6 secretion
by hypoxic stress per se remains debated; lack of or moderate
inductions of IL-6 protein secretion by hypoxic stress have
been described in other cellular models; a significant IL-6
induction may require prolonged hypoxia or reoxygenation
steps. Hypoxic stress was found associated with an increased
expression of IL-6 mRNA, as shown in fibroblasts, vascular
smooth cells, endothelial cells, astrocytes or cardiac myo-
cytes, and TECs, after a brief or a prolonged hypoxic chal-
lenge [40–44]. Mechanisms linking signaling pathways
activated by hypoxia to the increased expression of IL-6
mRNA remain to be fully understood; however, some cues
may be brought by transcription studies that show
increased transcription of the IL-6 gene upon hypoxic
stress [40–43]. Indeed, the IL-6 gene promoter contains a
hypoxia-responsive element [45].
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Figure 4: Induction of HIF-1α and HIF-2α and endoplasmic reticulum stress in HK-2 cells grown under hypoxic conditions; (a) HIF-1α and
HIF-2α are induced in response to hypoxic stress. Top panel: HK-2 cells were grown under hypoxic conditions for the indicated times and
immunoblotting with anti-HIF-1α or anti-HIF-2α antibodies performed on cell lysates (β-tubulin was used as loading controls); bottom
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The stimulation of IL-6 secretion by CD154 suggests a
regulatory role for CD40 signaling in IL-6 production under
hypoxic conditions. Lack of stabilization of IL-6 protein or
mRNA and measurement of nascent RNAs indicates that a
main mechanism underlying CD154 stimulatory effect is
stimulation of IL-6 transcription. CD40 signaling controls
the transcription of IL-6 gene in a variety of cells [46, 47].
IL-6 mRNA is unstable, which is the case for several cyto-
kines and growth factors, a phenomenon believed to be crit-
ical to the kinetics of the inflammatory response; however,
there is little characterization of IL-6 posttranscriptional
regulators, and the regulation of IL-6 gene expression may
be to a large extent transcriptional. IL-6 was also found in
intracellular stores in some cells, allowing another potential
mechanism for rapid IL-6 mobilization [48, 49].
Rapid and sustained induction of IL-6 secretion is likely to
be necessary to mount an immediate inflammatory response
in the context of tissue injury. In an inflammatory environ-
ment, there are multiple potential sources for CD154, as var-
ious immune cells express CD154 and release its soluble form
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Figure 5: CD154 stimulates early IL-6 production by HK-2 cells under hypoxic conditions. (a) HK-2 cells were grown under hypoxic
conditions for 3 hours in the presence or not of increasing rsCD154 concentrations and IL-6 measured by ELISA in cell culture
supernatants (n = 3, ∗significant relatively to control). (b) HK-2 cells were grown under hypoxic conditions for the indicated times in the
presence or not (control) of rsCD154 and IL-6 measured by ELISA in cell culture supernatants (n = 3, ∗significant relatively to control).
(c) HK-2 cells were grown under hypoxic conditions for 3 or 24 hours, followed by a 24-hour culture in normoxic conditions in the
presence or not (control) of rsCD154 and IL-6 measured by ELISA in cell culture supernatants (n = 4, ∗significant relatively to control).
(d) HK-2 cells were grown 1 or 3 hours under hypoxic conditions in the presence or not (control) of rsCD154 (control) and IL-6
concentrations measured in cell lysates (n = 3; ∗significant relatively to control).
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when stimulated by inflammatory signals [18]. Platelets are
the principal reservoir of CD154 in blood, being readily pres-
ent and activated in inflamed tissues an important mecha-
nism that provides CD154 in the inflammatory milieu [50].
In vivo, higher platelet reactivity and response to agonists
observed in low O2 conditions suggest that hypoxia favors
platelet activation [51, 52]. Whether in vivo hypoxia per se
is an inducer of platelet activation remains debated. It must
be stressed, however, that the in vivo hypoxic/inflammatory
environment is a complex one and can lead to platelet activa-
tion via multiple mechanisms, including the liberation of
alarmins. Platelet activation in AKI is likely to result from
gathered mechanisms, including blood flow impairment,
ongoing inflammation, and hypoxia in the tubular microcir-
culation, leading to CD154 expression on platelets, the
release of sCD154, and the release of CD154-expressing
microvesicles. Indeed, there are signs of platelet activation
in ischemic or sepsis AKI rodent models [53]. The rapid
kinetics of CD154 expression make CD154 a potential front
line mediator of inflammation in the tubular microenviron-
ment. In the ischemic or sepsis-associated AKI, multiple
inflammation modifiers concur to tubular epithelium injury,
lesion, and regeneration [7]. Such a multiplicity underlines
the difficulty of addressing the responsibility of a particular
pathway. However, the powerful induction of IL-6 produc-
tion by CD154 in hypoxia may be part of the CD154 proin-
flammatory deleterious effects. Indeed, the release of
cytokines at site of injury is a hallmark feature of the early
inflammatory response, and IL-6 is a key pathophysiological
player in AKI tubular injury [54, 55]. Moreover, IL-6 serum
level is an early marker of organ dysfunction and predicts
poor outcome and renal recovery in critically ill patients with
AKI [56]. Interestingly, the inhibition of CD40 signaling has
demonstrated encouraging protective effects in a kidney
ischemia-reperfusion injury model [20]. The initial steps of
acute inflammation are dependent on early response cyto-
kines such as IL-1β, TNF-α, and IL-6 [39]. However, we
did not observe an upregulation of IL-1β and TNF-α even
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Figure 6: CD154 induces IL-6 mRNA in HK-2 cells grown under hypoxic conditions. (a) HK-2 cells were grown 3 hours under hypoxic
conditions in the presence or absence of rsCD154 and IL-6 mRNA expression analyzed by RT-qPCR. Data are normalized to cells grown
in hypoxic conditions in the absence of rsCD154 (n = 6; ∗significant relatively to control condition). (b) HK-2 cells were grown 3 hours
under hypoxic conditions in DMEM containing or not rsCD154 and actinomycin D, and IL-6 mRNA expression analyzed by RT-qPCR.
Data are normalized to cells grown in control condition (n = 6, ∗significant relatively to control, ∗∗significant relatively to rsCD154
condition). (c) HK-2 cells were grown 1 hour under hypoxic conditions in the presence or not of rsCD154 and cycloheximide (CHX),
cells were lysed, and IL-6 was measured in cell lysates by ELISA (n = 4, total protein amount in cell lysates did not differ between
conditions; ∗significant relatively to control, ∗∗significant relatively to rsCD154 condition). (d) CD154 stimulates IL-6 gene transcription
in hypoxic conditions. HK-2 cells were grown 3 hours under hypoxic conditions in the presence or absence of rsCD154 in DMEM, and a
nascent RNA capture assay was used to monitor the change in de novo IL-6 mRNA synthesis. Data are normalized to cells grown in
hypoxic condition without rsCD154 (n = 4, ∗significant relatively to control).
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in the presence of CD154 within a 3-hour short-term hypoxic
stress (data not shown). Although we have not studied other
proinflammatory cytokines, it is therefore tempting to specu-
late that the CD154/CD40 dyad exerts a specific proinflam-
matory role at very early stages of tubular injury and that
one of the underlying mechanisms involves the induction
of IL-6 production.
The amplification of XBP-1mRNA splicing by CD154 in
hypoxia suggests a link between the UPR and CD40 signal-
ing. Alternative XBP-1 mRNA splicing is induced by CD40
triggering [32, 57, 58]. Our results confirm that CD154 is
an UPR regulator. In fact, many recent evidences point to
the regulated nature of the UPR [3, 4]. The IRE-1/XBP-1
pathway is linked to inflammation, and activation of the
IRE-1 pathway in kidney epithelial cells activates the NF-κB
pathway and secretion of inflammatory cytokines [38]. The
regulation of XBP-1 splicing by CD40 signaling may there-
fore represent another regulatory interface in inflammation,
which will deserve further studies.
As the CD40 pathway holds a central position in
inflammation and contributes to multiple inflammatory
disorders, inhibition of the CD40-CD154 pathway is an
actively pursued strategy to treat inflammatory disorders.
The administration of anti-CD154 neutralizing antibodies
is effective in animal models but unfortunately causes
thromboembolism, and various alternative strategies are
sought for, such as the inhibition of CD40 signaling interme-
diates with peptides. We tested chloroquine as it was found to
have anti-inflammatory properties, although the mecha-
nisms involved remain ill-understood. Moreover, chloroquine
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Figure 7: Chloroquine alleviates the CD154-mediated induction of IL-6 in HK-2 cells. (a) HK-2 cells were preincubated with chloroquine
(50 μg/mL) and then incubated for 3 hours at 0.1% O2 in the presence or not of rsCD154; IL-6 protein was measured by ELISA in the
cell culture supernatants (n = 6, ∗significant relatively to control, ∗∗significant relatively to rsCD154 condition). (b) Dose effect
experiments: HK-2 cells were preincubated with the indicated concentrations of chloroquine and then incubated for 3 hours at 0.1% O2
in the presence or not of rsCD154; IL-6 protein was measured by ELISA in the cell culture supernatants (n = 7, ∗significant relatively
to control, ∗∗significant relatively to rsCD154 condition). (c) HK-2 cells were incubated for 3 hours at 0.1% O2 in the presence or not
of rsCD154, hydrocortisone (HC) and acetylsalicylic acid (ASA), and IL-6 protein measured by ELISA in cell culture supernatants
(n = 4, ∗significant relatively to control).
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confers protection in endotoxin shock and sepsis-induced AKI
[59–62]. There is a strong association between the levels of
systemic inflammatory mediators including IL-6 and the
development of sepsis-induced AKI, suggesting a key respon-
sibility of these mediators, including proinflammatory
cytokines. IL-6 is a key contributor to AKI [9, 63]. Chloro-
quine can reduce the expression of IL-6 mRNA as in LPS-
stimulated monocyte/macrophages; mechanisms were found
to be partly due to accelerated mRNA decay [64]. The down-
regulatory action of chloroquine on the expression of inflam-
matory mediators can involve various mechanisms, such as
at the mRNA level as shown, for example, for TNF-α
[22, 65] or at the protein level [64, 66]. How chloroquine
intersects with and inhibits the CD40 signaling remains to
be further studied. However, the inhibitory effect of chloro-
quine on inflammatory cytokine production such as IL-6,
coupled to the fact that chloroquine can also inhibit CD154
expression, as in T cells [67], suggests that this drug may have
an interest as a useful adjunct in the clinical setting, for exam-
ple, in conditions associated with AKI, such as in sepsis.
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Supplementary Materials
Supplemental Material and Methods: primary antibodies
used in this study: antibodies to BiP (Cell Signaling, Danvers,
USA), calnexin (Stressgen, Ann Arbor, USA), eIF2α (Cell
Signaling), phospho-eIF2α (Cell Signaling), ERK1/2 (Cell
Signaling), phospho-ERK1/2 (Cell Signaling), JNK (Santa
Cruz Biotechnology, Heidelberg, FRG), phospho-JNK (Santa
Cruz Biotechnology), Akt (Cell Signaling), phospho-Akt
(Cell Signaling), HIF-1α (Sigma-Aldrich, Saint-Quentin-
Fallavier, France), β-tubulin (Abcam, Paris, France), and
HIF-2α rabbit antibody D9E3 (Cell Signaling Technologies,
London, UK) were used in Western blot experiments. Anti-
bodies to human CD40 (H-10, Santa Cruz Biotechnology or
mAb89 (a gift from Dr. Jacques Banchereau, Baylor Institute
for Immunology Research, Dallas)) were used in flow cytom-
etry experiments. Rabbit polyclonal anti-CD40 antibody
(Biosource International, USA) was used in immunofluores-
cence. Supplemental Figure 1: CD154 amplifies XBP-1
mRNA splicing in anoxia-reoxygenation conditions. HK-2
cells were treated for 1 hour with 50ng/mL antimycin A, a
mitochondrial respiratory chain blocking agent, in the pres-
ence or not of rsCD154 at a concentration of 100 ng/mL; in
these conditions, XBP-1 mRNA splicing was moderately
induced but no effect of CD154 on XBP-1 mRNA splicing
was detectable (R0). Antimycin A was removed and culture
continued in normoxic conditions in the presence or not of
rsCD154 and the spliced/unspliced ratio of XBP-1 (XBP1
s/u) mRNA in HK-2 cells measured at the indicated times
by RT-qPCR (n = 4, ∗significant relatively to T0 condition,
p < 0:05). Supplemental Figure 2: CD154 induces IL-6
mRNA expression in HK-2 cells in hypoxic conditions.
HK-2 cells were grown under hypoxic conditions for 3 hours
in Lumox tissue culture plates (A) or in standard tissue
culture plates (B) in the presence or not of rsCD154; IL-6
protein was measured by ELISA in cell culture supernatants
(A, n = 5, ∗significant relatively to control conditions, p <
0:05); B, n = 3, ∗significant relatively to control conditions,
p < 0:05). (Supplementary Materials)
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